NO20033785L - Farmasöytisk formulering - Google Patents

Farmasöytisk formulering

Info

Publication number: NO20033785L
Authority: NO; Norway
Prior art keywords: pharmaceutical formulation; formulation; pharmaceutical
Prior art date: 2001-02-27

Application number

NO20033785A

Other languages

English (en)

Other versions

NO20033785D0 (no

Inventor

Nicola Bateman

Julie Cahill

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-27

Filing date

2003-08-26

Publication date

2003-10-24

2001-02-27 Priority claimed from GB0104749A external-priority patent/GB2372444A/en

2001-07-19 Priority claimed from SE0102572A external-priority patent/SE0102572D0/xx

2003-08-26 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2003-08-26 Publication of NO20033785D0 publication Critical patent/NO20033785D0/no

2003-10-24 Publication of NO20033785L publication Critical patent/NO20033785L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20033785A 2001-02-27 2003-08-26 Farmasöytisk formulering NO20033785L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0104749A GB2372444A (en)	2001-02-27	2001-02-27	A pharmaceutical formulation comprising bicalutamide and a hydroxypropylmethylcellulose polymer
SE0102572A SE0102572D0 (sv)	2001-07-19	2001-07-19	Pharmaceutical formulation
PCT/GB2002/000766 WO2002067893A2 (en)	2001-02-27	2002-02-22	Pharmaceutical formulation comprising bicalutamide

Publications (2)

Publication Number	Publication Date
NO20033785D0 NO20033785D0 (no)	2003-08-26
NO20033785L true NO20033785L (no)	2003-10-24

Family

ID=26245766

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20033785A NO20033785L (no)	2001-02-27	2003-08-26	Farmasöytisk formulering

Country Status (22)

Country	Link
US (1)	US20040067257A1 (no)
EP (1)	EP1368001B1 (no)
JP (2)	JP3548566B2 (no)
KR (1)	KR20030077042A (no)
CN (1)	CN1503662A (no)
AR (1)	AR032912A1 (no)
AT (1)	ATE307571T1 (no)
CA (1)	CA2439366A1 (no)
CZ (1)	CZ20032225A3 (no)
DE (1)	DE60206889T2 (no)
EE (1)	EE200300416A (no)
HU (1)	HUP0302847A3 (no)
IL (1)	IL157389A0 (no)
IS (1)	IS6915A (no)
MX (1)	MXPA03007641A (no)
NO (1)	NO20033785L (no)
NZ (1)	NZ527532A (no)
PL (1)	PL365746A1 (no)
RU (1)	RU2003128971A (no)
SK (1)	SK10722003A3 (no)
UY (1)	UY27186A1 (no)
WO (1)	WO2002067893A2 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0103424D0 (sv) *	2001-10-15	2001-10-15	Astrazeneca Ab	Pharmaceutical formulation
SE0103838D0 (sv) *	2001-11-16	2001-11-16	Astrazeneca Ab	Pharmaceutical formulation & product
TWI355276B (en) *	2003-01-14	2012-01-01	Akira Tsuji	Gastrointestinal absorption enhancer mediated by p
US20050008691A1 (en) *	2003-05-14	2005-01-13	Arturo Siles Ortega	Bicalutamide compositions
WO2005074991A1 (ja) *	2004-02-09	2005-08-18	Kabushiki Kaisha Sangi	抗腫瘍剤
KR100539706B1 (ko) *	2005-01-25	2005-12-28	지엘팜텍 주식회사	타크로리무스 및 장용성 고분자를 함유하는 고체분산체
CN101128195A (zh) *	2005-02-23	2008-02-20	阿斯利康(瑞典)有限公司	用于递送增加的稳态血浆水平的比卡鲁胺
US8293274B2 (en) *	2005-04-06	2012-10-23	Kabushiki Kaisha Sangi	Intestinal absorptive anti-tumor agent
US7785629B2 (en) *	2005-06-21	2010-08-31	Helm Ag	Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
JP5052051B2 (ja) *	2006-06-16	2012-10-17	トーアエイヨー株式会社	腸溶性顆粒剤及びその製造方法
US20080045600A1 (en) *	2006-08-17	2008-02-21	Gawande Rahul S	Bicalutamide compositions
WO2008063888A2 (en)	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
MX2010000617A (es)	2007-07-17	2010-05-17	Plexxikon Inc	Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
WO2009038112A1 (ja)	2007-09-21	2009-03-26	Shionogi & Co., Ltd.	Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
JP5204452B2 (ja) *	2007-10-02	2013-06-05	日医工株式会社	ビカルタミド含有製剤
EP2219624A2 (en) *	2007-11-08	2010-08-25	Glaxo Group Limited	Pharmaceutical formulations
AU2010232670B2 (en)	2009-04-03	2015-07-09	F. Hoffmann-La Roche Ag	Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
US8329724B2 (en)	2009-08-03	2012-12-11	Hoffmann-La Roche Inc.	Process for the manufacture of pharmaceutically active compounds
CN101987086B (zh) *	2009-08-03	2012-07-18	北京化工大学	一种超细比卡鲁胺口服片剂及其制备方法
MA33975B1 (fr)	2009-11-06	2013-02-01	Plexxikon Inc	Composés et méthodes de modulation des kinases et leurs indications d'emploi
BR112012015016B8 (pt)	2009-12-18	2021-05-25	Catalent France Beinheim Sa	formulação farmacêutica, forma de dosagem farmacêutica entérica e uso de uma formulação
CN102525876B (zh) *	2010-12-15	2014-03-12	西安力邦医药科技有限责任公司	阿司匹林固体分散体、其制备方法、药物组合物和用途
CN102552103B (zh) *	2010-12-20	2013-11-20	西安力邦医药科技有限责任公司	拉米夫定固体分散体、其制备方法、药物组合物和用途
HUE040136T2 (hu)	2011-02-07	2019-02-28	Plexxikon Inc	Vegyületek és eljárások kináz modulációra és azok indikációi
TWI558702B (zh)	2011-02-21	2016-11-21	普雷辛肯公司	醫藥活性物質的固態形式
US9150570B2 (en)	2012-05-31	2015-10-06	Plexxikon Inc.	Synthesis of heterocyclic compounds
US20140179749A1 (en)	2012-09-11	2014-06-26	Bend Research	Formulations of enzalutamide
CA2955747A1 (en) *	2014-08-07	2016-02-11	Pharmacyclics Llc	Novel formulations of a bruton's tyrosine kinase inhibitor
KR102348320B1 (ko)	2014-12-05	2022-01-10	아라곤 파마슈티컬스, 인코포레이티드	항암 조성물
KR102387089B1 (ko)	2014-12-05	2022-04-14	아라곤 파마슈티컬스, 인코포레이티드	항암 조성물
CN107854435B (zh) *	2016-12-15	2019-01-22	华领医药技术（上海）有限公司	葡萄糖激酶激活剂的口服制剂及其制备方法
KR20210151185A (ko)	2019-04-11	2021-12-13	알.피.쉐러 테크놀러지즈 엘엘씨	난투과성 단백질, 펩타이드 및 소분자의 경구 전달을 위한 제형
GB2584341B (en) *	2019-05-31	2023-03-01	Gw Res Ltd	Cannabinoid formulations
US11173291B2 (en) *	2020-03-20	2021-11-16	The Regents Of The University Of California	Implantable drug delivery devices for localized drug delivery
US11344526B2 (en)	2020-03-20	2022-05-31	The Regents Of The University Of California	Implantable drug delivery devices for localized drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3372965D1 (en) *	1982-07-23	1987-09-17	Ici Plc	Amide derivatives
JP2527107B2 (ja) *	1991-04-16	1996-08-21	日本新薬株式会社	固体分散体の製造方法
AU1687395A (en) *	1994-01-21	1995-08-08	Sepracor, Inc.	Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US20030059471A1 (en) *	1997-12-15	2003-03-27	Compton Bruce Jon	Oral delivery formulation
JP2004525164A (ja) *	2001-04-02	2004-08-19	アストラゼネカアクチボラグ	４−シアノ−トリフルオロ−３−（４−フルオロフェニルスルホニル）−２−ヒドロキシ−２−メチルプロピオノ−ｍ−トルイジドとＰＶＰを含む固体医薬組成物
SE0103424D0 (sv) *	2001-10-15	2001-10-15	Astrazeneca Ab	Pharmaceutical formulation
SE0103839D0 (sv) *	2001-11-16	2001-11-16	Astrazeneca Ab	Pharmaceutical formulation & product

2002
- 2002-02-22 KR KR10-2003-7011178A patent/KR20030077042A/ko not_active Withdrawn
- 2002-02-22 EE EEP200300416A patent/EE200300416A/xx unknown
- 2002-02-22 DE DE60206889T patent/DE60206889T2/de not_active Expired - Fee Related
- 2002-02-22 PL PL02365746A patent/PL365746A1/xx not_active Application Discontinuation
- 2002-02-22 CN CNA028087356A patent/CN1503662A/zh active Pending
- 2002-02-22 CA CA002439366A patent/CA2439366A1/en not_active Abandoned
- 2002-02-22 HU HU0302847A patent/HUP0302847A3/hu unknown
- 2002-02-22 MX MXPA03007641A patent/MXPA03007641A/es unknown
- 2002-02-22 WO PCT/GB2002/000766 patent/WO2002067893A2/en not_active Ceased
- 2002-02-22 US US10/468,276 patent/US20040067257A1/en not_active Abandoned
- 2002-02-22 CZ CZ20032225A patent/CZ20032225A3/cs unknown
- 2002-02-22 IL IL15738902A patent/IL157389A0/xx unknown
- 2002-02-22 AT AT02712105T patent/ATE307571T1/de not_active IP Right Cessation
- 2002-02-22 JP JP2002567261A patent/JP3548566B2/ja not_active Expired - Fee Related
- 2002-02-22 SK SK1072-2003A patent/SK10722003A3/sk unknown
- 2002-02-22 NZ NZ527532A patent/NZ527532A/xx unknown
- 2002-02-22 EP EP02712105A patent/EP1368001B1/en not_active Expired - Lifetime
- 2002-02-22 RU RU2003128971/15A patent/RU2003128971A/ru not_active Application Discontinuation
- 2002-02-26 UY UY27186A patent/UY27186A1/es not_active Application Discontinuation
- 2002-02-27 AR ARP020100712A patent/AR032912A1/es not_active Application Discontinuation
2003
- 2003-08-15 IS IS6915A patent/IS6915A/is unknown
- 2003-08-26 NO NO20033785A patent/NO20033785L/no not_active Application Discontinuation
2004
- 2004-02-18 JP JP2004041583A patent/JP2004143185A/ja active Pending

Also Published As

Publication number	Publication date
DE60206889T2 (de)	2006-07-27
IS6915A (is)	2003-08-15
WO2002067893A2 (en)	2002-09-06
WO2002067893A3 (en)	2003-01-16
IL157389A0 (en)	2004-05-12
CA2439366A1 (en)	2002-09-06
ATE307571T1 (de)	2005-11-15
JP2004521918A (ja)	2004-07-22
JP3548566B2 (ja)	2004-07-28
US20040067257A1 (en)	2004-04-08
MXPA03007641A (es)	2003-12-04
NO20033785D0 (no)	2003-08-26
NZ527532A (en)	2004-12-24
SK10722003A3 (sk)	2004-02-03
RU2003128971A (ru)	2005-03-10
EP1368001A2 (en)	2003-12-10
CN1503662A (zh)	2004-06-09
PL365746A1 (en)	2005-01-10
UY27186A1 (es)	2002-09-30
HUP0302847A3 (en)	2005-05-30
AR032912A1 (es)	2003-12-03
CZ20032225A3 (cs)	2003-11-12
DE60206889D1 (de)	2005-12-01
EP1368001B1 (en)	2005-10-26
HUP0302847A2 (hu)	2003-12-29
JP2004143185A (ja)	2004-05-20
EE200300416A (et)	2003-12-15
KR20030077042A (ko)	2003-09-29

Publication	Publication Date	Title
NO20033384D0 (no)	2003-07-29	Farmasöytisk formulering
NO20033785L (no)	2003-10-24	Farmasöytisk formulering
NO20033556L (no)	2003-10-09	Farmasöytiske formuleringer
ITTO20010008A0 (it)	2001-01-10	Formulazione farmaceutica
FI20011478A0 (fi)	2001-07-05	Farmaseuttinen koostumus
PT1501534E (pt)	2006-09-29	Formulacoes farmaceuticas
PL367180A1 (pl)	2005-02-21	Trwała kompozycja farmaceutyczna
NO20035627D0 (no)	2003-12-15	Farmasöytisk formulering
IS7051A (is)	2003-11-26	Lyfjasamsetningar
FI20022128L (fi)	2003-06-06	Farmaseuttinen koostumus
NO20042502L (no)	2004-08-09	Farmasoytisk formulering omfattende bicalutamid
NO20041485L (no)	2004-04-13	Farmasoytisk formulering omfattende (R)-bicalutamid
DE10291905D2 (de)	2004-05-27	Pharmazeutische Zusammensetzung
NO20015534D0 (no)	2001-11-12	Farmasöytisk blandeapparat
EE200300465A (et)	2003-12-15	Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
DE10107261B4 (de)	2005-03-10	Pharmazeutische Zusammensetzung
NO20041236L (no)	2004-03-24	Farmasoytisk formulering
SE0101171D0 (sv)	2001-04-02	Pharmaceutical formulation
SE0101325D0 (sv)	2001-04-12	Pharmaceutical formulation
SE0101326D0 (sv)	2001-04-12	Pharmaceutical formulation
SE0102069D0 (sv)	2001-06-21	Pharmaceutical formulation
SE0102572D0 (sv)	2001-07-19	Pharmaceutical formulation
SE0102957D0 (sv)	2001-09-04	Pharmaceutical formulation
SE0103565D0 (sv)	2001-10-25	Pharmaceutical formulation
EP1413314A4 (en)	2004-12-22	MEDICAL COMPOSITIONS

Legal Events

Date	Code	Title	Description
2006-10-02	FC2A	Withdrawal, rejection or dismissal of laid open patent application